Literature DB >> 3261667

HLA-DR2 association with excessive somnolence in narcolepsy does not generalize to sleep apnea and is not accompanied by systemic autoimmune abnormalities.

R L Rubin1, R M Hajdukovich, M M Mitler.   

Abstract

Recent reports that nearly all patients with narcolepsy have the HLA-DR2 phenotype suggest that autoimmunity may underly the etiology or pathogenesis of this disorder. Of 11 narcoleptic patients in the present study, 9 were HLA-DR2, confirming the strong association with this class II antigen but indicating that this is not an obligatory phenotype. In contrast only 3/10 patients with sleep apnea were HLA-DR2, suggesting that this form of excessive somnolence has a different etiopathogenesis. Significant levels of rheumatoid factor, antinuclear antibodies or autoantibodies to native DNA, denatured DNA, histones, Sjogren's syndrome B antigen, or Smith antigen were undetectable in sera from narcoleptic patients. Antibodies to rodent brain, primate brain stem, and neurocytotoxic antibodies were also not found. These results along with the absence of laboratory signs and clinical features of a systemic inflammatory process indicate that if narcolepsy is an autoimmune disease, the underlying lesion or pathologic condition may be confined to the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261667     DOI: 10.1016/0090-1229(88)90104-3

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  10 in total

Review 1.  Narcolepsy: immunological aspects.

Authors:  Sebastiaan Overeem; John Logan Black; Gert Jan Lammers
Journal:  Sleep Med Rev       Date:  2008-03-04       Impact factor: 11.609

Review 2.  Genetics of narcolepsy and other sleep disorders.

Authors:  E Mignot
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

3.  Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin heavy-chain switch-like segment.

Authors:  E Mignot; C Wang; C Rattazzi; C Gaiser; M Lovett; C Guilleminault; W C Dement; F C Grumet
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

4.  Major histocompatibility class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in canine model.

Authors:  M Tafti; S Nishino; M S Aldrich; W Liao; W C Dement; E Mignot
Journal:  J Neurosci       Date:  1996-08-01       Impact factor: 6.167

5.  HLA haplotypes, polysomnography, and pedigrees in a case series of patients with narcolepsy.

Authors:  R Hayduk; P Flodman; M A Spence; M K Erman; M M Mitler
Journal:  Sleep       Date:  1997-10       Impact factor: 5.849

Review 6.  Benefits and risks of pharmacotherapy for narcolepsy.

Authors:  Merrill M Mitler; Roza Hayduk
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

7.  IgH (mu-switch and gamma-1) region restriction fragment length polymorphism in human narcolepsy.

Authors:  S M Singh; C F George; R N Ott; C Rattazzi; C Guilleminault; W C Dement; E Mignot
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

8.  Treatment of narcolepsy with methamphetamine.

Authors:  M M Mitler; R Hajdukovic; M K Erman
Journal:  Sleep       Date:  1993-06       Impact factor: 5.849

9.  Narcolepsy.

Authors:  M M Mitler; R Hajdukovic; M Erman; J A Koziol
Journal:  J Clin Neurophysiol       Date:  1990-01       Impact factor: 2.177

Review 10.  History of narcolepsy at Stanford University.

Authors:  Emmanuel J M Mignot
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.